These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 25246737

  • 21. Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice.
    Fabbroni M, Cantarini L, Caso F, Costa L, Pagano VA, Frediani B, Manganelli S, Galeazzi M.
    Mediators Inflamm; 2014; 2014():862969. PubMed ID: 25110401
    [Abstract] [Full Text] [Related]

  • 22. Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL.
    Fafá BP, Louzada-Junior P, Titton DC, Zandonade E, Ranza R, Laurindo I, Peçanha P, Ranzolin A, Hayata AL, Duarte A, Silveira IG, Costa I, Macieira JC, Guedes-Barbosa LS, Bertolo MB, Sauma MF, Silva MB, Freire M, Scheinberg MA, Fernandes V, Bianchi W, Miranda JR, Pinheiro GR, Carvalho HM, Brenol CV, Pereira IA, de Castro GR, de Morais JC, Oliveira SK, de Abreu MM, Toledo RA, Pinheiro MM, Vieira WP, Valim V, BIOBADABRASIL.
    Clin Rheumatol; 2015 May; 34(5):921-7. PubMed ID: 25851594
    [Abstract] [Full Text] [Related]

  • 23. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
    Malottki K, Barton P, Tsourapas A, Uthman AO, Liu Z, Routh K, Connock M, Jobanputra P, Moore D, Fry-Smith A, Chen YF.
    Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
    [Abstract] [Full Text] [Related]

  • 24. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database.
    Wendling D, Joshi A, Reilly P, Jalundhwala YJ, Mittal M, Bao Y.
    Curr Med Res Opin; 2014 Dec; 30(12):2515-21. PubMed ID: 25252590
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea.
    Lee SK, Kim SY, Kim EY, Jung JY, Park MS, Kim YS, Kim SK, Chang J, Kang YA.
    Lung; 2013 Oct; 191(5):565-71. PubMed ID: 23728990
    [Abstract] [Full Text] [Related]

  • 27. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: post-hoc analyses from the GO-AFTER study.
    Smolen JS, Kay J, Matteson EL, Landewé R, Hsia EC, Xu S, Zhou Y, Doyle MK.
    Ann Rheum Dis; 2014 Oct; 73(10):1811-8. PubMed ID: 23897769
    [Abstract] [Full Text] [Related]

  • 28. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, Zink A.
    JAMA; 2009 Feb 18; 301(7):737-44. PubMed ID: 19224750
    [Abstract] [Full Text] [Related]

  • 29. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.
    Elkayam O, Caspi D, Reitblatt T, Charboneau D, Rubins JB.
    Semin Arthritis Rheum; 2004 Feb 18; 33(4):283-8. PubMed ID: 14978666
    [Abstract] [Full Text] [Related]

  • 30. Reduction of biological agent dose in rheumatic diseases: descriptive analysis of 153 patients in clinical practice conditions.
    Inciarte-Mundo J, Hernández MV, Rosario V, Ruiz-Esquide V, Cabrera-Villalba S, Ramírez J, Cañete JD, Sanmartí R.
    Reumatol Clin; 2014 Feb 18; 10(1):10-6. PubMed ID: 23876791
    [Abstract] [Full Text] [Related]

  • 31. TNFα antagonist therapy does not increase the Epstein-Barr virus burden in patients with rheumatoid arthritis or ankylosing spondylitis.
    Couderc M, Payet S, Henquell C, Dubost JJ, Soubrier M.
    Joint Bone Spine; 2010 Oct 18; 77(5):414-7. PubMed ID: 20542718
    [Abstract] [Full Text] [Related]

  • 32. Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival.
    Flouri I, Markatseli TE, Voulgari PV, Boki KA, Papadopoulos I, Settas L, Zisopoulos D, Skopouli FN, Iliopoulos A, Bertsias GK, Geborek P, Drosos AA, Boumpas DT, Sidiropoulos P.
    Semin Arthritis Rheum; 2014 Feb 18; 43(4):447-57. PubMed ID: 24012040
    [Abstract] [Full Text] [Related]

  • 33. Incidence of septic arthritis in patients with ankylosing spondylitis and seropositive rheumatoid arthritis following TNF inhibitor therapy.
    Kim HW, Han M, Jung I, Ahn SS.
    Rheumatology (Oxford); 2023 Aug 01; 62(8):2740-2747. PubMed ID: 36562569
    [Abstract] [Full Text] [Related]

  • 34. Low rates of adherence for tumor necrosis factor-α inhibitors in Crohn's disease and rheumatoid arthritis: results of a systematic review.
    Fidder HH, Singendonk MM, van der Have M, Oldenburg B, van Oijen MG.
    World J Gastroenterol; 2013 Jul 21; 19(27):4344-50. PubMed ID: 23885145
    [Abstract] [Full Text] [Related]

  • 35. Retention on anti-tumour necrosis factor therapy: the Waikato experience.
    Ip K, Hartley L, Solanki K, White D.
    N Z Med J; 2015 May 29; 128(1415):34-40. PubMed ID: 26117510
    [Abstract] [Full Text] [Related]

  • 36. Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis.
    Canhão H, Rodrigues AM, Mourão AF, Martins F, Santos MJ, Canas-Silva J, Polido-Pereira J, Pereira Silva JA, Costa JA, Araújo D, Silva C, Santos H, Duarte C, da Silva JA, Pimentel-Santos FM, Branco JC, Karlson EW, Fonseca JE, Solomon DH.
    Rheumatology (Oxford); 2012 Nov 29; 51(11):2020-6. PubMed ID: 22843791
    [Abstract] [Full Text] [Related]

  • 37. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
    Tang B, Rahman M, Waters HC, Callegari P.
    Clin Ther; 2008 Jul 29; 30(7):1375-84. PubMed ID: 18691998
    [Abstract] [Full Text] [Related]

  • 38. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
    Bonafede M, Fox KM, Watson C, Princic N, Gandra SR.
    Adv Ther; 2012 Aug 29; 29(8):664-74. PubMed ID: 22886712
    [Abstract] [Full Text] [Related]

  • 39. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
    Favalli EG, Pontikaki I, Becciolini A, Biggioggero M, Ughi N, Romano M, Crotti C, Gattinara M, Gerloni V, Marchesoni A, Meroni PL.
    Clin Rheumatol; 2017 Aug 29; 36(8):1747-1755. PubMed ID: 28597133
    [Abstract] [Full Text] [Related]

  • 40. Neurological adverse events in patients receiving anti-TNF therapy: a prospective imaging and electrophysiological study.
    Kaltsonoudis E, Zikou AK, Voulgari PV, Konitsiotis S, Argyropoulou MI, Drosos AA.
    Arthritis Res Ther; 2014 Jun 17; 16(3):R125. PubMed ID: 24938855
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.